Rate My Professor Ying Sun

Sun has made significant contributions through numerous peer-reviewed publications in prestigious journals. Notable works include 'FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1' (Molecular Therapy, 2025), 'Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease' (Human Molecular Genetics, 2024), 'iPSC-derived neural precursor cells engineering GBA1 recovers acid β-glucosidase deficiency and diminishes α-synuclein and neuropathology' (Molecular Therapy: Methods & Clinical Development, 2023), 'PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases' (Proceedings of the National Academy of Sciences, 2023), 'Earlier-onset, more severe neurodegeneration in PGRN KO mice with a decreased dose of D409V Gba1' (Molecular Genetics and Metabolism, 2023), and 'A brain penetrant progranulin-derived biologic protects against neuronopathic Gaucher disease' (Molecular Genetics and Metabolism, 2023). She has also contributed editorially, co-authoring 'Editorial: Neuronopathic lysosomal storage diseases - specific neuronal characteristics and therapeutic approaches' (Frontiers in Molecular Neuroscience, 2022). These efforts underscore her impact on developing translational therapies for neurodegenerative lysosomal storage disorders.